bioMérieux Presentation: Importance of CAR-T Cell Therapy Quality Control Throughout the Patient's Journey
Wednesday, May 29, 2024 06:45 PM - 07:00 PM
Exhibit Hall - Theatre B
Global Showcase Presentation
Presenter(s)
Quality control (QC) tests are done throughout the whole manufacturing process and need:
• To offer the best performance and adaptability to CAR-T cell therapy manufacturers.
• To ensure the healthcare professionals (HCPs) that the product is safe, not contaminated and that the cells are of a good quality. When CAR-T cell therapies are manufactured internally within hospital settings, the challenge is even greater due to the lack of standardization and GMP constraints that are difficult to reach for hospitals.
As a global team, industry together with hospitals and HCPs are continuously making efforts to reduce the time from bench to bedside, so that eligible patients can receive these innovative treatments
Session Objectives:
• Understand and visualize the different steps of QC and the potential impacts on patients’ journey.
• Highlight the importance of a close collaboration between CAR-T cell therapy manufacturers, QA/QC providers and HCPs.
• Explore how to constantly adapt to this changing environment and more specifically to the increasing involvement of the hospital setting in the CAR-T cell therapy manufacturing landscape.
- Narjes Armanet, MD, PhD, Senior Global Medical Advisor, bioMérieux, FRANCE
Quality control (QC) tests are done throughout the whole manufacturing process and need:
• To offer the best performance and adaptability to CAR-T cell therapy manufacturers.
• To ensure the healthcare professionals (HCPs) that the product is safe, not contaminated and that the cells are of a good quality. When CAR-T cell therapies are manufactured internally within hospital settings, the challenge is even greater due to the lack of standardization and GMP constraints that are difficult to reach for hospitals.
As a global team, industry together with hospitals and HCPs are continuously making efforts to reduce the time from bench to bedside, so that eligible patients can receive these innovative treatments
Session Objectives:
• Understand and visualize the different steps of QC and the potential impacts on patients’ journey.
• Highlight the importance of a close collaboration between CAR-T cell therapy manufacturers, QA/QC providers and HCPs.
• Explore how to constantly adapt to this changing environment and more specifically to the increasing involvement of the hospital setting in the CAR-T cell therapy manufacturing landscape.
SPONSORED BY:
